Skip to main content

Table 4 Table of 3-point MACE for CVOT studies to date.

From: Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

  Antidiabetic drug 3P-MACE hazard ratio (HR) p value
PROactive Pioglitazone 0.84 (95% CI 0.72–0.98) 0.02
ORIGIN Insulin glargine 1.02 (95% CI 0.94–1.11) NS
SAVOR Saxagliptin 1.00 (95% CI 0.89–1.12) NS
EXAMINE Alogliptin 0.96 (95% CI 0.80–1.15) NS
ELIXA Lixisenatide 1.02 (95% CI 0.89–1.17) NS
TECOS Sitagliptin 0.98 (95% CI 0.89–1.08) NS
EMPA-REG OUTCOME® Empagliflozin 0.86 (95% CI 0.74–0.99) 0.038
LEADER® Liraglutide 0.87 (95% CI 0.78–0.97) 0.01
SUSTAIN™-6 Semaglutide 0.74 (95% CI 0.58–0.95) < 0.001a
CANVAS-program Canagliflozin 0.86 (95% CI 0.75–0.97) 0.02
  1. This is not a head-to-head comparison
  2. CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), NS not significant
  3. aSUSTAIN™-6 was a non-inferiority study, and testing for superiority was not a pre-specified endpoint